ARDELYX, INC. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARDELYX, INC. stock issued during period, value, issued for services for the quarter ending 2026-06-30 was $185.00K, a 41.27% decline year-over-year.
- ARDELYX, INC. stock issued during period, value, issued for services for the quarter ending 2025-12-31 was $0.00.
- ARDELYX, INC. stock issued during period, value, issued for services for the quarter ending 2025-09-30 was $0.00.
- ARDELYX, INC. stock issued during period, value, issued for services for the quarter ending 2025-06-30 was $315.00K, a 22.57% increase year-over-year.
- ARDELYX, INC. stock issued during period, value, issued for services for fiscal 2025 was $315.00K, a 22.57% increase from fiscal 2024.
- ARDELYX, INC. stock issued during period, value, issued for services for fiscal 2024 was $257.00K, a 23.74% decline from fiscal 2023.
- ARDELYX, INC. stock issued during period, value, issued for services for fiscal 2023 was $337.00K, a 13.59% decline from fiscal 2022.
- ARDELYX, INC. stock issued during period, value, issued for services for fiscal 2022 was $390.00K, a 105.26% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2026-06-30 | $185.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $315.00K 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | |
| 2025-06-30 | $315.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $257.00K 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | |
| 2024-06-30 | $257.00K 10-Q · filed 2025-08-04 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $337.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | |
| 2023-06-30 | $337.00K 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $390.00K 10-K · filed 2025-02-20 |
| 2022-09-30 | $390.00K 10-Q · filed 2023-10-31 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $190.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $190.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $310.00K 10-K · filed 2023-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2020-06-30 | $310.00K 10-Q · filed 2021-08-13 | |
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $312.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $300.00K 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $311.00K 10-Q · filed 2020-08-06 | |
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $303.00K 10-K · filed 2021-03-08 |
| 2018-09-30 | $300.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $302.00K 10-Q · filed 2019-08-09 | |
| 2017-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $201.00K 10-K · filed 2019-03-06 |
| 2017-09-30 | $200.00K 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $200.00K 10-Q · filed 2018-08-07 | |
| 2016-12-31 | $187.00K 10-K · filed 2019-03-06 | |
| 2016-06-30 | $200.00K 10-Q · filed 2017-08-09 | |
| 2015-12-31 | $194.00K 10-K · filed 2018-03-14 | |
| 2014-12-31 | $208.00K 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |